RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).
Hansjochen Wilke
Honoraria - Lilly
Eric Van Cutsem
Research Funding - Lilly
Sang Cheul Oh
No relevant relationships to disclose
Gyorgy Bodoky
No relevant relationships to disclose
Yasuhiro Shimada
Honoraria - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical
Shuichi Hironaka
No relevant relationships to disclose
Naotoshi Sugimoto
Honoraria - Osaka GI Cancer Meeting
Research Funding - Meeting of HER-2 Positive Cancer
Oleg N. Lipatov
No relevant relationships to disclose
Tae-You Kim
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Atsushi Ohtsu
No relevant relationships to disclose
Philippe Rougier
Disclosure not yet available
Michael Emig
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Roberto Carlesi
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Kumari Chandrawansa
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Kei Muro
No relevant relationships to disclose